Recently several promising future therapy directions have been reviewed in SCLC including Poly [ADP-ribose] polymerase (PARP) inhibitors in combination with chemotherapy and targeting of histone-lysine N-methyltransferase EZH2 (135). This evidence concerns the gene PARP1 and small cell lung carcinoma.